ATE412429T1 - Impfstoffzusammensetzung im gemisch mit einem alkylphosphatidylcholin - Google Patents

Impfstoffzusammensetzung im gemisch mit einem alkylphosphatidylcholin

Info

Publication number: ATE412429T1
Authority: AT; Austria
Prior art keywords: alkylphosphatidylcholine; vaccine composition; composition mixed; pharmaceutical composition; additionally contains
Prior art date: 2003-11-17

Application number

AT04805451T

Other languages

English (en)

Inventor

Jean Haensler

Original Assignee

Sanofi Pasteur

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-17

Filing date

2004-11-15

Publication date

2008-11-15

2004-11-15 Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur

2008-11-15 Application granted granted Critical

2008-11-15 Publication of ATE412429T1 publication Critical patent/ATE412429T1/de

Links

229960005486 vaccine Drugs 0.000 title abstract 2
239000000427 antigen Substances 0.000 abstract 2
102000036639 antigens Human genes 0.000 abstract 2
108091007433 antigens Proteins 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 1
230000000844 anti-bacterial effect Effects 0.000 abstract 1
230000036436 anti-hiv Effects 0.000 abstract 1
239000000824 cytostatic agent Substances 0.000 abstract 1
230000001085 cytostatic effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
150000008105 phosphatidylcholines Chemical class 0.000 abstract 1
239000002423 protozoacide Substances 0.000 abstract 1
230000001549 tubercolostatic effect Effects 0.000 abstract 1
239000000814 tuberculostatic agent Substances 0.000 abstract 1
239000012646 vaccine adjuvant Substances 0.000 abstract 1
229940124931 vaccine adjuvant Drugs 0.000 abstract 1
239000012873 virucide Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Communicable Diseases (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Organic Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT04805451T 2003-11-17 2004-11-15 Impfstoffzusammensetzung im gemisch mit einem alkylphosphatidylcholin ATE412429T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0313406A FR2862306B1 (fr)	2003-11-17	2003-11-17	Composition vaccinale

Publications (1)

Publication Number	Publication Date
ATE412429T1 true ATE412429T1 (de)	2008-11-15

Family

ID=34508504

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04805451T ATE412429T1 (de)	2003-11-17	2004-11-15	Impfstoffzusammensetzung im gemisch mit einem alkylphosphatidylcholin

Country Status (23)

Country	Link
US (2)	US7344720B2 (de)
EP (1)	EP1696954B1 (de)
JP (1)	JP4638880B2 (de)
KR (1)	KR101136107B1 (de)
CN (1)	CN1882358B (de)
AT (1)	ATE412429T1 (de)
AU (1)	AU2004290943B2 (de)
BR (1)	BRPI0416670A (de)
CA (1)	CA2545086C (de)
CY (1)	CY1108498T1 (de)
DE (1)	DE602004017504D1 (de)
DK (1)	DK1696954T3 (de)
ES (1)	ES2311875T3 (de)
FR (1)	FR2862306B1 (de)
IL (1)	IL175573A (de)
LT (1)	LT5435B (de)
LV (1)	LV13457B (de)
NO (1)	NO20062779L (de)
PL (1)	PL1696954T3 (de)
PT (1)	PT1696954E (de)
SI (1)	SI1696954T1 (de)
WO (1)	WO2005049080A1 (de)
ZA (1)	ZA200603522B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100752990B1 (ko) *	2006-08-02	2007-08-30	주식회사 대웅	나노리포좀 및 천연 추출물을 포함하는 피부 질환의 예방또는 치료용 조성물
TWI444384B (zh) *	2008-02-20	2014-07-11	Gilead Sciences Inc	核苷酸類似物及其在治療惡性腫瘤上的用途
CN101959527B (zh)	2008-03-05	2016-04-20	赛诺菲巴斯德有限公司	一种使含佐剂的疫苗组合物稳定的方法
WO2010130896A2 (fr)	2009-05-14	2010-11-18	Sanofi Pasteur	Procédé pour adjuver le lipopolysaccharide (lps) des bactéries à gram-négatif
CA2761924C (fr)	2009-05-14	2017-10-31	Sanofi Pasteur	Vaccin meningocoque a base de lipooligosaccharide (los) provenant de souches modifiees de neisseria meningitidis d'immunotype l6
AU2010247253A1 (en) *	2009-05-14	2012-01-12	Sanofi Pasteur	Method for detoxification of lipopolysaccharide (LPS) or of lipid a of gram-negative bacteria
EP2578974A1 (de)	2011-10-05	2013-04-10	Sanofi Pasteur Sa	Verfahrenslinie zur Herstellung von gefriergetrockneten Partikeln
JP5761143B2 (ja) *	2011-11-02	2015-08-12	株式会社リコー	撮像ユニット、撮像ユニットを搭載した車両
US20140147475A1 (en) *	2012-11-29	2014-05-29	Antonius Arnoldus Christiaan Jacobs	Vaccine to protect a ruminant against pneumonia caused by pasteurella multocida
AU2014234452B2 (en)	2013-03-18	2018-02-22	Intervet International B.V.	Vaccine to protect a ruminant against pneumonia caused by Mannheimia haemolytica
BR112016031039B1 (pt)	2014-07-21	2022-02-15	Sanofi Pasteur Sa	Dispositivo de alimentação de líquido para a geração de gotículas, linha de processo para a produção de partículas liofilizadas e processos para preparar uma composição de vacina compreendendo

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6100064A (en)	1984-04-06	2000-08-08	Chiron Corporation	Secreted viral proteins useful for vaccines and diagnostics
FR2773156B1 (fr)	1997-12-26	2000-03-31	Biovacs Inc	Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
ES2260291T3 (es)	2000-09-28	2006-11-01	Chiron Corporation	Microparticulas para la administracion de acidos nucleicos heterologos.
DE60117164T2 (de) *	2000-11-07	2006-08-03	Immuno Vaccine Technologies Inc., Halifax	Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
US7303881B2 (en) *	2004-04-30	2007-12-04	Pds Biotechnology Corporation	Antigen delivery compositions and methods of use

2003
- 2003-11-17 FR FR0313406A patent/FR2862306B1/fr not_active Expired - Fee Related
2004
- 2004-11-15 ZA ZA200603522A patent/ZA200603522B/en unknown
- 2004-11-15 CN CN2004800338756A patent/CN1882358B/zh not_active Expired - Fee Related
- 2004-11-15 EP EP04805451A patent/EP1696954B1/de not_active Expired - Lifetime
- 2004-11-15 AU AU2004290943A patent/AU2004290943B2/en not_active Ceased
- 2004-11-15 SI SI200430990T patent/SI1696954T1/sl unknown
- 2004-11-15 DK DK04805451T patent/DK1696954T3/da active
- 2004-11-15 JP JP2006540508A patent/JP4638880B2/ja not_active Expired - Fee Related
- 2004-11-15 BR BRPI0416670 patent/BRPI0416670A/pt not_active IP Right Cessation
- 2004-11-15 AT AT04805451T patent/ATE412429T1/de active
- 2004-11-15 PL PL04805451T patent/PL1696954T3/pl unknown
- 2004-11-15 ES ES04805451T patent/ES2311875T3/es not_active Expired - Lifetime
- 2004-11-15 US US10/989,154 patent/US7344720B2/en not_active Expired - Fee Related
- 2004-11-15 KR KR1020067009520A patent/KR101136107B1/ko not_active Expired - Fee Related
- 2004-11-15 WO PCT/FR2004/002911 patent/WO2005049080A1/fr not_active Ceased
- 2004-11-15 PT PT04805451T patent/PT1696954E/pt unknown
- 2004-11-15 DE DE200460017504 patent/DE602004017504D1/de not_active Expired - Lifetime
- 2004-11-15 CA CA 2545086 patent/CA2545086C/en not_active Expired - Fee Related
2006
- 2006-05-11 IL IL175573A patent/IL175573A/en active IP Right Grant
- 2006-05-15 LV LVP-06-70A patent/LV13457B/lv unknown
- 2006-05-17 LT LT2006036A patent/LT5435B/lt not_active IP Right Cessation
- 2006-06-14 NO NO20062779A patent/NO20062779L/no not_active Application Discontinuation
2008
- 2008-01-09 US US11/971,751 patent/US7767658B2/en not_active Expired - Fee Related
- 2008-11-11 CY CY081101283T patent/CY1108498T1/el unknown

Also Published As

Publication number	Publication date
ZA200603522B (en)	2007-07-25
ES2311875T3 (es)	2009-02-16
IL175573A0 (en)	2006-09-05
LT2006036A (en)	2007-05-25
SI1696954T1 (sl)	2009-04-30
CN1882358B (zh)	2011-02-02
FR2862306A1 (fr)	2005-05-20
WO2005049080A1 (fr)	2005-06-02
FR2862306B1 (fr)	2008-05-30
US7767658B2 (en)	2010-08-03
US7344720B2 (en)	2008-03-18
EP1696954B1 (de)	2008-10-29
CY1108498T1 (el)	2014-04-09
US20050208060A1 (en)	2005-09-22
EP1696954A1 (de)	2006-09-06
CN1882358A (zh)	2006-12-20
PT1696954E (pt)	2008-11-25
WO2005049080B1 (fr)	2005-09-01
AU2004290943A1 (en)	2005-06-02
AU2004290943B2 (en)	2009-08-27
LV13457B (en)	2007-01-20
PL1696954T3 (pl)	2009-04-30
US20080131446A1 (en)	2008-06-05
KR101136107B1 (ko)	2012-04-17
CA2545086C (en)	2011-11-08
CA2545086A1 (en)	2005-06-02
DK1696954T3 (da)	2009-02-23
DE602004017504D1 (de)	2008-12-11
IL175573A (en)	2010-06-30
JP2007511585A (ja)	2007-05-10
JP4638880B2 (ja)	2011-02-23
NO20062779L (no)	2006-08-15
KR20060127385A (ko)	2006-12-12
BRPI0416670A (pt)	2007-02-13
LT5435B (lt)	2007-07-25

Legal Events

Date

Code

Title

Description

2009-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1696954

Country of ref document: EP

Publication	Publication Date	Title
CY1108498T1 (el)	2014-04-09	Συνθεση εμβολιου η οποια περιεχει ως εκδοχο μια αλκυλφωσφατιδυλοχολινη
CY1106801T1 (el)	2012-05-23	Νεες ετεροκυκλικες ενωσεις, η παρασκευη τους και η χρηση τους ως φαρμακα, ιδιαιτερα ως αντιβακτηριακα
CY1108823T1 (el)	2014-04-09	Παραγωγα 2-υδροξυ-3-ετεροαρυλινδολης ως αναστολεις της gsk3
MX9404749A (es)	1995-01-31	Heterociclos de fenilo como inhibidores de cox-2.
CY1108295T1 (el)	2014-02-12	Παραγωγα μονοσακχαριτη αβερμεκτινης τα οποια εχουν παρασιτοκτονες ιδιοτητες
CY1107081T1 (el)	2012-10-24	Λιπαρα οξεα, ως παραγοντες επιβιωσης κι ενεργοποιησης ουδετεροφιλων
CY1115719T1 (el)	2017-01-25	Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
EA200501098A1 (ru)	2006-02-24	Антибактериальные агенты
BR0316690A (pt)	2005-10-18	Composto, prodroga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
ATE181329T1 (de)	1999-07-15	Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
BRPI0507801A (pt)	2007-07-10	compostos de azetidina substituìda, processo para a preparação de compostos de azetidina substituìda, medicamento e uso de pelo menos um composto de azetidina substituìda
AR029795A1 (es)	2003-07-16	Derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos
ES2169242T3 (es)	2002-07-01	2-amino-benzoxazinonas para el tratamiento de infecciones virales.
BR0311810A (pt)	2005-03-15	Preparação revestida, processo para a produção e uso da mesma, processo para a produção de pelo menos uma ração e/ou aditivo para rações contendo pelo menos um diformiato, e, ração para animais
BRPI0617918B8 (pt)	2021-05-25	compostos de fórmula (i) e seu uso, medicamentos e composição farmacêutica
ITMI911853A1 (it)	1993-01-04	Sale del diclofenac, metodo di preparazione e composizioni farmaceutiche che lo contengono.
ATE399526T1 (de)	2008-07-15	Pharmazeutische und kosmetische formulierungen zur behandlung der nägel
EE200200599A (et)	2004-04-15	Tsüklipostiiniühend kasutamiseks diabeedivastase ravimina, seda sisaldav farmatseutiline preparaat,ühendi ja preparaadi valmistamine ning selleks vajalik mikroorganism
SI1970372T1 (sl)	2011-04-29	Soli 9-oksoakridin-10-ocetne kisline z 1-alkilamino-1-deoksi-polioli
EA200000374A2 (ru)	2000-12-25	Новые соединения 2,3-метаноаминокислоты, способ их получения и содержащие их фармацевтические композиции
PT1123937E (pt)	2004-09-30	Substancia gm-95 processo para a sua preparacao e a sua utilizacao
ES2192608T3 (es)	2003-10-16	Uso de derivados de alilamina tales como terbinafina, en la fabricacion de un medicamento para el tratamiento de la infeccion por helicobacter pylori de enfermedades asociadas.
AR031712A1 (es)	2003-10-01	Metodo y composicion
ES8306758A1 (es)	1983-06-01	Un procedimiento para la preparacion de un derivado de beta-lactama.
ES2109715T3 (es)	1998-01-16	Procedimiento para la preparacion de n-carbonilariliminas utiles en la sintesis de taxoides terapeuticamente activos.